Medical/Pharmaceuticals

NAVER D2SF Invests in AI-Driven Precision Medicine Company ImpriMed

* ImpriMed combines ex vivo functional testing with multimodal AI to support personalized cancer treatment decisions and drug development * The investment is part of ImpriMed's $10 million Series A2 bridge round as the company advances U.S. commercialization and expands into Asia * NAVER D2S...

2026-09-18 23:00 3309

Jiahui Health Highlights China's Growing Role in Global Medical Tourism at WTO Public Forum 2026

GENEVA, Sept. 18, 2026 /PRNewswire/ -- China is seeing growing momentum in inbound medical tourism, driven by expanding access to innovative therapies, visa facilitation and the development of internationally oriented healthcare services, Dr. John K. Hsiang, Chairman of Jiahui Health Executive Co...

2026-09-18 21:00 1998

2026 Tang Prize Award Ceremony Honors Six Laureates

Outstanding Achievements for Global Well-Being and Our Shared Future TAIPEI, Sept. 18, 2026 /PRNewswire/ -- The 2026 Tang Prize Award Ceremony brought together all six laureates in Taipei on September 18, with five receiving their awards in person and Biopharmaceutical Science laureate Dr. Steve...

2026-09-18 19:56 599

Rosti Group highlights cutting-edge medical solutions at Medical Fair Asia 2026

SINGAPORE, Sept. 18, 2026 /PRNewswire/ --  A report from Ringiertrade. The recently concluded Medical Fair Asia 2026, Southeast Asia's Leading International Healthcare Trade Fair for the medical and healthcare sectors, provided opportunities for leading companies to unveil their products and ser...

2026-09-18 09:13 2824

A robust adjusted EBIT margin of 18.8%, driven by solid organic revenue growth of 7.4%

PARIS, Sept. 18, 2026 /PRNewswire/ --  Virbac Headquarters, Carros, France * H1 2026 delivered a robust revenue growth of +7.4% and an adjusted EBIT margin of 18.8% at CERS: ○  Revenue growth is coming from both segm...

2026-09-18 00:33 2316

ADVANCION RELEASES 2025 SUSTAINABILITY REPORT: "SAFE BY CHOICE. SUSTAINABLE BY DESIGN."

Advancion's fifth annual report highlights the Company's progress in safety, sustainable innovation and responsible operations BUFFALO GROVE, Ill., Sept. 17, 2026 /PRNewswire/ -- Advancion Corporation ("Advancion" or the "Company"), a global leader in life sciences buffers and proprietary specia...

2026-09-17 23:48 2523

Datasea's AI Agent Digital Marketing Services Enter Scaled Commercial Deployment, with Five Agreements Representing Potential Annualized Service Volume of Up to Approximately US$89.4 Million (RMB600 Million)

Five-customer AI agent services advance into actual delivery; CEO reiterates long-term confidence through a previously disclosed US$1.0 million Rule 10b5-1 share purchase plan BEIJING, Sept. 17, 2026 /PRNewswire/ -- Datasea Intelligent Technology Ltd. (NASDAQ: DTSS) ("Datasea" or the "Company"),...

2026-09-17 21:10 4502

New Peer-Reviewed Study Confirms Innovative Technology Shatters ESR's Four-Hour Deadline

ALCOR Scientific's iSED® analyzers reshape lab logistics and improve patient care for one of medicine's most widely used tests * Seven times longer stability, independently validated. ESR samples on ALCOR Scientific's iSED analyzer remained accurate for up to 28 hours at room temperature and 4...

2026-09-17 21:00 1967

ZEISS expands retinal imaging portfolio with new ZEISS ALTA DUO 300

ZEISS' new multimodal solution combines automated OCT and fundus imaging to support simplified and efficient retinal assessment across a broader range of eye care practices. JENA, Germany, Sept. 17, 2026 /PRNewswire/ -- ZEISS Medical Technology, one of the world's leading medical technology comp...

2026-09-17 21:00 3091

There's No One-Size-Fits-All for Treating Older Adults with Cancer, According to New NCCN Patient Resource

New guideline for patients and caregivers explains the importance of assessments to tailor cancer care to every person, regardless of age. PLYMOUTH MEETING, Pa., Sept. 17, 2026 /PRNewswire/ -- Today, the National Comprehensive Cancer Network® (NCCN®)—an alliance of leading cancer centers—is publ...

2026-09-17 20:20 1466

Dr. Alison Armour agrees to become Chief Medical Officer of Alpha Fusion, as Company Advances Integration of At-211 Businesses with Curadh MTR

— Combining Both Companies' Astatine At-211 Assets, Development Capabilities, and Supply Chains to Create a Global Targeted Alpha Therapy Company — TOKYO, Sept. 17, 2026 /PRNewswire/ -- Alpha Fusion Inc. ("Alpha Fusion"), a clinical-stage company with an advanced At-211 drug platform, and Curadh ...

2026-09-17 19:00 2256

111 Inc. Receives Unsolicited Preliminary Non-Binding Proposal to Acquire the Company

SHANGHAI, Sept. 17, 2026 /PRNewswire/ -- 111 Inc. ( "111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company in China, today announced that its Board of Directors (the "Board") has received an unsolicited preliminary non-binding proposal letter (the "Proposal") dat...

2026-09-17 16:25 5721

WuXi XDC Out-Licenses WuXiTecan-2 Payload-Linker Technology Platform to Ona Therapeutics to Advance Novel ADC Research and Development

SHANGHAI, Sept. 17, 2026 /PRNewswire/ -- WuXi XDC Cayman Inc. ("WuXi XDC", stock code: 2268.HK), a leading global CRDMO (Contract Research, Development, and Manufacturing Organization) specializing in antibody-drug conjugates (ADCs) and other bioconjugates, today announced an out-licensing collab...

2026-09-17 16:09 2553

Clarivate Reveals Citation Laureates 2026 Recognizing Transformative Scientific Breakthroughs

22 researchers honored for Nobel-class discoveries, including pioneers of GLP-1 medicines and other world-changing advances LONDON, Sept. 17, 2026 /PRNewswire/ -- Clarivate Plc ...

2026-09-17 15:05 1819

111, Inc. Announces Second Quarter 2026 Unaudited Financial Results

* Transition from An Asset-Heavy Business Model to An Asset-Light Business Model * Ongoing Investment and Adoption of AI Agents Making Workforce Streamlining Possible * Net Revenue of Promotional Products (1) Increased by 121% and Gross Profit Rose by 120% Year-over-Year * Total Marketpla...

2026-09-17 15:00 6655

Akeso's EGFR/TROP2 Bispecific ADC AK158D1 Granted NMPA Phase I Clearance for Advanced Solid Tumors, Marking Its Fourth Clinical-Stage ADC Candidate

HONG KONG, Sept. 17, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that AK158D1, its investigational next-generation bispecific antibody-drug conjugate (ADC) targeting EGFR and TROP2, has secured Phase I clinical trial clearance from the Center for Drug Evaluatio...

2026-09-17 14:34 1803

Tianjin University Leads World's 1st ISO Standard for Single-Herb TCM Formula Granules

TIANJIN, China, Sept. 16, 2026 /PRNewswire/ -- The International Organization for Standardization (ISO) has published ISO 21756:2026, the world's first international standard for single-herb Traditional Chinese Medicine (TCM) formula granules. Titled Traditional Chinese Medicine —Salvia miltiorrh...

2026-09-17 13:25 2148

Piramal Pharma Solutions Advances Sustainability Efforts with Solar Power Plant Addition at Morpeth, UK Site

* Piramal Pharma Solutions is installing a ground-mounted solar power plant (4.3 MWp) at its integrated drug substance and drug product site in Morpeth, UK. * The new plant will provide renewable energy directly to the site through a behind-the-meter setup, supporting Piramal's commitment to re...

2026-09-16 22:28 3540

Datasea Expands into China's Trillion-RMB Silver Economy Through Strategic Cooperation in AI Elderly Care Robots

Datasea plans to combine its AI agent and digital platform capabilities with its partner's robotics technologies and elderly care deployment experience to develop intelligent care solutions for China's rapidly growing silver economy BEIJING, Sept. 16, 2026 /PRNewswire/ -- Datasea Intelligent Tech...

2026-09-16 21:28 4537

OncoC4 Receives FDA Fast Track Designation for Cesalatamig, an Investigational PD-1/VEGF Bispecific Antibody

* Cesalatamig is Currently Being Evaluated in Phase 1/2 Studies in the United States (NCT06635785 ) and in China (CTR20253261

2026-09-16 19:00 2190
1234567 ... 643

Week's Top Stories